Lentiviral vectors (LV) were first used clinically in 2003 (Levine et al 2006), demonstrating high safety and transduction efficiency. Since then more than 100 clinical trials have been successfully conducted or are in progress (http://www.abedia.com/wiley/vectors.php). This includes the significant success seen in treating certain B cell leukemias with LV-modified T cells expressing chimeric antigen receptors (CARs) specific for CD19 (Porter et al. 2011) and to repair monogenic gene disorders with LV-modified CD34 stem cells (Cartier et al 2009).
If you are interested in basic T cell or HSC transduction protocols, please contact us.